Rickettsia typhi is the etiologic agent of both epidemic and endemic typhus.
| Test Name and Number | Recommended Use | Limitations | Follow Up |
|---|---|---|---|
| Rickettsia typhi (Typhus Fever) Antibodies, IgG & IgM by IFA 0050384 Method: Semi-Quantitative Indirect Fluorescent Antibody |
Confirm presence of Rickettsia typhi |
Initial testing may not be helpful; base treatment on clinical and other laboratory assessment While the presence of IgM antibodies suggests current or recent infection, low levels of IgM antibodies may occasionally persist for >12 months postinfection Any antibody reactivity to Rickettsia typhi antigen should also be considered group reactive for the typhus fever group (R. prowazekii) |
If test results are equivocal, repeat testing in 10-14 days |
| Febrile Antibodies Panel 2001789 Method: Semi-Quantitative Agglutination/Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Immunoblot |
Use to confirm presence of disease; not recommended for initial testing Panel includes IgM R. typhi antibody by ELISA testing, as well as testing for antibodies to Brucella, R. rickettsii, Salmonella O and H antigens |
Base treatment decision on clinical and other laboratory assessments Cross reactivity with Brucella and Salmonella |
|
| CBC with Platelet Count and Automated Differential 0040003 Method: Automated Cell Count/Differential |
Nonspecific testing for R. typhi Shows thrombocytopenia in 40% of cases |
||
| Urea Nitrogen, Serum or Plasma 0020023 Method: Quantitative Spectrophotometry |
Nonspecific testing for R. typhi Elevated in ~30% of cases |
||
| Hepatic Function Panel 0020416 Method: Quantitative Enzymatic/Quantitative Spectrophotometry |
Nonspecific testing for R. typhi Bilirubin elevated in ~20% of cases |
||
| Creatinine, Serum or Plasma 0020025 Method: Quantitative Enzymatic |
Nonspecific testing for R. typhi |